Canada Markets closed

Syros Pharmaceuticals, Inc. (0S9.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
0.6570-0.0130 (-1.94%)
At close: 08:06AM CEST
Sign in to post a message.
  • G
    George
    When it comes to investing,we want our money to grow with the highest rates of return,and the lowest risk possible.While there are no shortcuts to getting rich,but there are smart ways to go about it...
  • T
    TBone
    All young biotechs are highly speculative by their nature. I have an open limit buy order @ $.98, I am not going to raise it because I do not "chase" stock prices. I remain interested in the company so I will keep the order open, at least for now. At this point, my opinion is that it is "over bought," though.
  • D
    David
    Going to zero
  • a
    art
    When are earnings ? confusing because Yahoo says today?
  • j
    jerzy
    this is ready to run
  • B
    Bokoyito
    what is happening?
  • T
    Terrence
    bought my first 1000 shares when I was on ecstasy based on yahoo's 1 yr prediction
  • T
    THE-MAX
    Gotta luv bottom feedin' these days... What's my name? hehe THE MAX
  • Y
    Yahoo Finance Insights
    Syros Pharmaceuticals reached an all time low at 0.85
  • Y
    Yahoo Finance Insights
    Syros Pharmaceuticals reached an all time low at 0.85
  • Y
    Yahoo Finance Insights
    Syros Pharmaceuticals reached an all time low at 0.86
  • Y
    Yahoo Finance Insights
    Syros Pharmaceuticals reached an all time low at 0.89
  • Y
    Yahoo Finance Insights
    Syros Pharmaceuticals reached an all time low at 0.90
  • g
    george
    Hey there, I think that now the shorts have covered the positions the only way is up unless something negative arises, good luck to everyone and be patient!
  • C
    Chris
    Read the report from Syros. They are telling us that the trials are going very well as indirectly as they can possibly say without giving away the news since the trial phase is not over. Buy now and you will not regret it
  • V
    V.
    This stock will probably be a winner this year, as it lost approx. 70% last year without any significant negative news. Bought today at $3.26. Good luck to all who are invested in SYRS as well!
  • t
    tim
    Syros Pharma founder and CEO...Nancy Simonian, M.D.

    Nancy is the founding CEO of Syros and has an established track record of value creation in biotechnology. Prior to Syros, she was Chief Medical Officer at Millennium Pharmaceuticals, and previously, Vice President of Clinical Development at Biogen. Nancy has overseen the successful development of numerous medicines. Under Nancy’s leadership as Chief Medical Officer at Millennium, VELCADE became a mainstay of treatment for multiple myeloma. Nancy led development of Millennium’s clinical pipeline, including NINLARO for hematologic malignancies and ENTYVIO for inflammatory bowel disease. At Biogen, Nancy played a central role in developing AVONEX and TYSABRI for multiple sclerosis. Nancy started her career as an assistant professor at Harvard Medical School and neurology staff at Massachusetts General Hospital (MGH). She trained in neurology and internal medicine at MGH and graduated with a bachelor’s degree in biology from Princeton. She is currently a member of the board of directors of Evelo Biosciences, Seattle Genetics, the Biotechnology Innovation Organization (BIO) and the Damon Runyon Cancer Research Foundation.
  • C
    Chris
    The positive from today’s announcement is that Syros has actually learned a lot from SY1365 so it is starting a new trial with an oral dosage vs the intravenous one. In other words the knowledge gained is being used to further develop a new drug. By no means a complete failure just a slower progress. The conference call from this morning is available on their website.
  • t
    tim
    You are now able to buy shares at a 70% discount to what Incyte (INCY) paid for their 793k shares...

    "Under the terms of the agreement, Incyte will pay Syros $10 million upfront – including $2.5 million in cash and $7.5 million in prepaid research and development (R&D) – and purchase a total of $10 million in Syros common stock at $12.61 per share."

    https://www.businesswire.com/news/home/20180108005822/en/Incyte-Syros-Announce-Global-Target-Discovery-Validation
  • Y
    Yahoo Finance Insights
    Syros Pharmaceuticals is up 8.53% to 1.40